1 이승환, "정신분열병의 인지기능 향상을 위한 새로운 약물개발 - MATRICS의 소개 -" 대한정신약물학회 16 (16): 272-278, 2005
2 Pinkham AE, "The social cognition psychometric evaluation study: Results of the expert survey and RAND panel" 40 : 813-823, 2014
3 Tamminga CA, "The neurobiology of cognition in schizophrenia" 67 : 9-13, 2006
4 Kirkpatrick B, "The NIMH-MATRICS consensus statement on negative symptoms" 32 : 214-219, 2006
5 Nuechterlein KH, "The MATRICS consensus cognitive battery, part 1:Test selection, reliability, and validity" 165 : 203-213, 2008
6 Green MF, "Stimulating the development of drug treatments to im-prove cognition in schizophrenia" 3 : 159-180, 2007
7 Kahn RS, "Schizophrenia is a cognitive illness: Time for a change in focus" 70 : 1107-1112, 2013
8 Opler LA, "Pharmacotherapy of cognitive deficits in schizophrenia" 19 : 142-156, 2014
9 Arneric SP, "Neuronal nicotinic receptors:A perspective on two decades of drug discovery research" 74 : 1092-1101, 2007
10 Yasuhara A, "Metabotropic glutamate receptors: Potential drug targets for psychiatric disorders" 4 : 20-36, 2010
1 이승환, "정신분열병의 인지기능 향상을 위한 새로운 약물개발 - MATRICS의 소개 -" 대한정신약물학회 16 (16): 272-278, 2005
2 Pinkham AE, "The social cognition psychometric evaluation study: Results of the expert survey and RAND panel" 40 : 813-823, 2014
3 Tamminga CA, "The neurobiology of cognition in schizophrenia" 67 : 9-13, 2006
4 Kirkpatrick B, "The NIMH-MATRICS consensus statement on negative symptoms" 32 : 214-219, 2006
5 Nuechterlein KH, "The MATRICS consensus cognitive battery, part 1:Test selection, reliability, and validity" 165 : 203-213, 2008
6 Green MF, "Stimulating the development of drug treatments to im-prove cognition in schizophrenia" 3 : 159-180, 2007
7 Kahn RS, "Schizophrenia is a cognitive illness: Time for a change in focus" 70 : 1107-1112, 2013
8 Opler LA, "Pharmacotherapy of cognitive deficits in schizophrenia" 19 : 142-156, 2014
9 Arneric SP, "Neuronal nicotinic receptors:A perspective on two decades of drug discovery research" 74 : 1092-1101, 2007
10 Yasuhara A, "Metabotropic glutamate receptors: Potential drug targets for psychiatric disorders" 4 : 20-36, 2010
11 Javitt DC, "Glutamatergic theories of schizophrenia" 47 : 4-16, 2010
12 Paz RD, "Glutamatergic dysfunction in schizophrenia: From basic neuroscience to clinical psychophar-macology" 18 : 773-786, 2008
13 Lin CH, "Glutamate signaling in the pathophys-iology and therapy of schizophrenia" 100 : 665-677, 2012
14 Green MF, "Commentary on “cognition in schizophrenia”" 23 : 786-787, 2013
15 Goldberg TE, "Comment on “cognition in schizophrenia:Summary nice consultation meeting 2012”" 23 : 788-789, 2013
16 Ochoa EL, "Cognitive deficits in schizophrenia: Focus on neuronal nicotinic acetylcholine receptors and smoking" 27 : 609-639, 2007
17 Nutt D, "Cognition in schizophrenia: Summary nice consultation meet-ing 2012" 23 : 769-778, 2013
18 Green MF, "Cognition in schizophrenia: Past, present, and future" 1 : 1-9, 2014
19 Tonmoy S, "Cognition in schizophrenia: Impairments, Im-portance and Treatment Strategies" Oxford university press 3-335, 2000
20 Keefe RS, "Clinical trials of potential cognitive-enhancing drugs in schizophrenia: What have we learned so far?" 39 : 417-435, 2013
21 Green MF, "Approaching a consensus cognitive battery for clinical tri-als in schizophrenia: the NIMH-MATRICS conference to select cog-nitive domains and test criteria" 56 : 301-307, 2004
22 이정구, "Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study" 대한신경정신의학회 9 (9): 166-173, 2012
23 Green MF, "Adapting social neuroscience mea-sures for schizophrenia clinical trials, part 1: Ferrying paradigms across perilous waters" 39 : 1192-1200, 2013
24 Shim JC, "Ad-junctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: A random-ized double-blind placebo-controlled trial" 37 : 660-668, 2012
25 Lee BJ, "A 12-week, double-blind, placebo-con-trolled trial of donepezil as an adjunct to haloperidol for treating cog-nitive impairments in patients with chronic schizophrenia" 21 : 421-427, 2007
26 Lee SW, "A 12-week, double-blind, pla-cebo-controlled trial of galantamine adjunctive treatment to con-ventional antipsychotics for the cognitive impairments in chronic schizophrenia" 22 : 63-68, 2007